Is (poly-) substance use associated with impaired inhibitory control? A mega-analysis controlling for confounders.

Executive Function / physiology Humans Inhibition, Psychological Psychomotor Performance / physiology Substance-Related Disorders / physiopathology
Go/No-Go task Mega-analysis Polysubstance use Response inhibition Stop-signal task

Journal

Neuroscience and biobehavioral reviews
ISSN: 1873-7528
Titre abrégé: Neurosci Biobehav Rev
Pays: United States
ID NLM: 7806090

Informations de publication

Date de publication:
10 2019
Historique:
received: 11 01 2019
revised: 10 06 2019
accepted: 07 07 2019
pubmed: 19 7 2019
medline: 1 7 2020
entrez: 19 7 2019
Statut: ppublish

Résumé

Many studies have reported that heavy substance use is associated with impaired response inhibition. Studies typically focused on associations with a single substance, while polysubstance use is common. Further, most studies compared heavy users with light/non-users, though substance use occurs along a continuum. The current mega-analysis accounted for these issues by aggregating individual data from 43 studies (3610 adult participants) that used the Go/No-Go (GNG) or Stop-signal task (SST) to assess inhibition among mostly "recreational" substance users (i.e., the rate of substance use disorders was low). Main and interaction effects of substance use, demographics, and task-characteristics were entered in a linear mixed model. Contrary to many studies and reviews in the field, we found that only lifetime cannabis use was associated with impaired response inhibition in the SST. An interaction effect was also observed: the relationship between tobacco use and response inhibition (in the SST) differed between cannabis users and non-users, with a negative association between tobacco use and inhibition in the cannabis non-users. In addition, participants' age, education level, and some task characteristics influenced inhibition outcomes. Overall, we found limited support for impaired inhibition among substance users when controlling for demographics and task-characteristics.

Identifiants

DOI: 10.1016/j.neubiorev.2019.07.006 PMID: 31319124
pubmed: 31319124
pii: S0149-7634(18)30633-X
doi: 10.1016/j.neubiorev.2019.07.006
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

288-304

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA021403
Pays : United States

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Yang Liu (Y)

Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Addiction, Development, and Psychopathology (ADAPT) Lab, Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: liu.yang.ocean1@gmail.com.

Wery P M van den Wildenberg (WPM)

Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Brain and Cognition Center, University of Amsterdam, Amsterdam, the Netherlands.

Ysanne de Graaf (Y)

Faculty of Science (FNWI), University of Amsterdam, Amsterdam, the Netherlands.

Susan L Ames (SL)

School of Community and Global Health, Claremont Graduate University, Claremont, CA, USA.

Alexander Baldacchino (A)

Division of Population and Behavioural Sciences, St Andrews University Medical School, University of St Andrews, St Andrews, Scotland, UK.

Ragnhild Bø (R)

Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway.

Fernando Cadaveira (F)

Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Galicia, Spain.

Salvatore Campanella (S)

Laboratoire de Psychologie Médicale et d'Addictologie, ULB Neuroscience Institute (UNI), CHU Brugmann-Université Libre de Bruxelles (U.L.B.), Brussels, Belgium.

Paul Christiansen (P)

Department of Psychological Sciences, University of Liverpool, Liverpool, UK.

Eric D Claus (ED)

The Mind Research Network and Lovelace Biomedical and Environmental Research Institute, Albuquerque, NM, USA.

Lorenza S Colzato (LS)

Leiden University, Cognitive Psychology Unit & Leiden Institute for Brain and Cognition, Leiden, the Netherlands.

Francesca M Filbey (FM)

Center for BrainHealth, School of Behavioral and Brain Sciences, The University of Texas at Dallas, TX, USA.

John J Foxe (JJ)

University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, USA.

Hugh Garavan (H)

Department of Psychiatry, University of Vermont, Burlington, USA.

Christian S Hendershot (CS)

Centre for Addiction and Mental Health, Campbell Family Mental Health Research Institute and Institute for Mental Health Policy Research, Toronto, Canada.

Robert Hester (R)

School of Psychological Sciences, University of Melbourne, Melbourne, Australia.

Jennifer M Jester (JM)

Department of Psychiatry, University of Michigan, MI, USA.

Hollis C Karoly (HC)

Institute of Cognitive Science, University of Colorado Boulder, CO, USA.

Anja Kräplin (A)

Work Group Addictive Behaviours, Risk Analyses and Risk Management, Faculty of Psychologie, Technische Universität Dresden, Germany.

Fanny Kreusch (F)

Department of Psychology, University of Liège, Belgium.

Nils Inge Landrø (NI)

Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Oslo, Norway.

Marianne Littel (M)

Department of Psychology, Erasmus University Rotterdam, Rotterdam, the Netherlands.

Sabine Loeber (S)

Department of Clinical Psychology and Psychotherapy, University of Bamberg, Bamberg, Germany.

Edythe D London (ED)

Department of Psychiatry and Biobehavioral Sciences at the University of California, Los Angeles, USA.

Eduardo López-Caneda (E)

Psychological Neuroscience Lab, Research Center in Psychology (CIPsi), School of Psychology, University of Minho, Braga, Portugal.

Dan I Lubman (DI)

Turning Point, Eastern Health and Eastern Health Clinical School, Monash University, Melbourne, Australia.

Maartje Luijten (M)

Behavioural Science Institute, Radboud University, Nijmegen, the Netherlands.

Cecile A Marczinski (CA)

Northern Kentucky University, Highland Heights, USA.

Jane Metrik (J)

Center for Alcohol and Addiction Studies, Brown University School of Public Health, Providence, USA.

Catharine Montgomery (C)

School of Natural Sciences and Psychology, Liverpool John Moores University, Liverpool, UK.

Harilaos Papachristou (H)

Maastricht University, Faculty of Psychology and Neuroscience, the Netherlands.

Su Mi Park (S)

Department of Psychiatry, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea; Department of Clinical Medical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea.

Andres L Paz (AL)

Department of Psychology, Charles Schmidt College of Science, Florida Atlantic University, USA.

Géraldine Petit (G)

Department of Psychological Sciences, University of Liverpool, Liverpool, UK.

James J Prisciandaro (JJ)

Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA.

Boris B Quednow (BB)

Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland.

Lara A Ray (LA)

University of California Los Angeles, Department of Psychology, Los Angeles, CA, USA.

Carl A Roberts (CA)

Department of Psychological Sciences, University of Liverpool, Liverpool, UK.

Gloria M P Roberts (GMP)

School of Psychiatry, University of New South Wales, Sydney, Australia.

Michiel B de Ruiter (MB)

Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Claudia I Rupp (CI)

Department of Psychiatry, Psychotherapy and Psychosomatic, Medical University Innsbruck, Austria.

Vaughn R Steele (VR)

The Mind Research Network and Lovelace Biomedical and Environmental Research Institute, Albuquerque, NM, USA.

Delin Sun (D)

Duke Brain Imaging and Analysis Center, Duke University School of Medicine, Durham, NC, USA; Mid-Atlantic Mental Illness Research, Education and Clinical Center (MIRECC), Durham, NC, USA.

Michael Takagi (M)

Child Neuropsychology Research Group, Murdoch Children's Research Institute, Melbourne, Australia; Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia.

Susan F Tapert (SF)

Department of Psychiatry, University of California, San Diego, USA.

Ruth J van Holst (RJ)

Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Institute for Addiction Research, Amsterdam, the Netherlands.

Antonio Verdejo-Garcia (A)

Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia.

Matthias Vonmoos (M)

Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, Psychiatric Hospital, University of Zürich, Zürich, Switzerland.

Marcin Wojnar (M)

Department of Psychiatry, Medical University of Warsaw, Warsaw, Poland.

Yuanwei Yao (Y)

State Key Laboratory of Cognitive Neuroscience and Learning and IDG/McGovern Institute for Brain Research, Beijing Normal University, Beijing, China.

Murat Yücel (M)

School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash Biomedical Imaging Facility, Monash University, Melbourne, Victoria, Australia.

Martin Zack (M)

Molecular Brain Science Research Section Centre for Addiction and Mental Health, Toronto, Canada.

Robert A Zucker (RA)

Department of Psychiatry, University of Michigan, MI, USA.

Hilde M Huizenga (HM)

Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Brain and Cognition Center, University of Amsterdam, Amsterdam, the Netherlands; Research Priority Area Yield, Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands.

Reinout W Wiers (RW)

Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands; Addiction, Development, and Psychopathology (ADAPT) Lab, Department of Psychology, University of Amsterdam, Amsterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Fonction exécutive › Is (poly-) substance use associated with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Is (poly-) substance use associated with...
questionsmedicales.fr › Phénomènes psychologiques › Théorie psychologique › Théorie psychanalytique › Inhibition (psychologie) › Is (poly-) substance use associated with...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Performance psychomotrice › Is (poly-) substance use associated with...
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Is (poly-) substance use associated with...